Dinesh Thummuri
University of Florida
H-index: 28
North America-United States
Top articles of Dinesh Thummuri
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Therapeutic agents and methods of treatment | 2023/10/26 | ||
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery | Sajid Khan Patrick Kellish Nick Connis Dinesh Thummuri Janet Wiegand | 2023/1/2 |
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers | Journal of Hematology & Oncology | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/3/9 |
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer | Proceedings of the National Academy of Sciences | Daniel R Principe Rui Xiong Yangfeng Li Thao ND Pham Suneel D Kamath | 2022/1/25 |
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 | Molecular cancer therapeutics | Dinesh Thummuri Sajid Khan Patrick W Underwood Peiyi Zhang Janet Wiegand | 2022/1/1 |
THERAPEUTICS AND TREATMENT METHODS | 2022/10/26 | ||
A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers | Cancer Research | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/6/15 |
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity | Nature communications | Dongwen Lv Pratik Pal Xingui Liu Yannan Jia Dinesh Thummuri | 2021/11/25 |
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition | Journal of medicinal chemistry | Pratik Pal Dinesh Thummuri Dongwen Lv Xingui Liu Peiyi Zhang | 2021/9/17 |
Hispolon inhibits RANKL induced osteoclast differentiation in vitro | Immunology Letters | Dinesh Thimmuri PA Shantanu NP Syamprasad Aasiya Khan Basveshwar Gawali | 2021/3/1 |
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity | Nature communications | Yonghan He Xuan Zhang Jianhui Chang Ha-Neui Kim Peiyi Zhang | 2020/4/24 |
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas | Journal of hematology & oncology | Yonghan He Raphael Koch Vivekananda Budamagunta Peiyi Zhang Xuan Zhang | 2020/12 |
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity | Dinesh Thummuri Xingui Liu Wanyi Hu Peiyi Zhang Sajid Khan | 2020/4/15 | |
A facile synthesis of ligands for the von Hippel–Lindau E3 ligase | Synthesis | Christian Steinebach Sabine Anna Voell Lan Phuong Vu Aleša Bricelj Izidor Sosič | 2020/9 |
Local administration of 4-Thiouridine, a novel molecule with potent anti-inflammatory properties, protects against experimental colitis and arthritis | International Immunopharmacology | Manish Kumar Jeengar Sudeep Chenna Narendra Dinesh Thummuri Mattias Magnusson VGM Naidu | 2020/8/1 |
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines | European journal of medicinal chemistry | Xuan Zhang Yonghan He Peiyi Zhang Vivekananda Budamagunta Dongwen Lv | 2020/8/1 |
Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy | Cancer Research | DR Principe M Narbutis S Kumar A Park et. al | 2020 |
Co-Authors
